Arguably, the most important unmet need in the field is the monitoring of disease activity and treatment response in patients with treatable neuropathies such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), hereditary transthyretin-related amyloidosis (hATTR), and anti-MAG neuropathy. The gene discussed is MAG; the disease is familial amyloid neuropathy.